Powered by
GUMC announces launch of Phase II Parkinson's disease trial
Feb 27, 2017 - Marketline Newswire

Georgetown University Medical Center (GUMC) has announced the launch of a Phase II clinical trial to study the safety of the cancer drug nilotinib and its effects on clinical outcomes and biomarkers in people with Parkinson's disease.

GUMC is recruiting volunteers for the study in collaboration with its clinical partner, MedStar Georgetown University Hospital. The clinical trial is a Phase II, randomized, double-blind, placebo-controlled study designed to evaluate the safety and tolerabili

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 10 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox